FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of Immune System Therapeutics

Australian anti-cancer drug picked as one of the world’s top 10 most promising new drug products in 2011

18-Oct-2011 - Immune System Therapeutics (IST) announced its lead anti-cancer product, MDX-1097, had been recognized as one of Windhover's Top 10 most promising new drug products for 2011. Windhover is a provider of business information to the pharmaceutical, biotechnology, and medical device industries. ...

cancer Immune System Therapeutics multiple myeloma +1

Immune System Therapeutics moves to reach international markets with appointment of new Chief Executive Officer

06-Oct-2011 - Immune System Therapeutics Limited (IST) announced Chief Executive Officer Alan Liddle had informed the board of his decision to retire from the role of CEO. International executive and healthcare specialist, Dr Calum McKinlay, has been appointed Chief Executive Officer, effective from the end of ...

appointments Chief Executive Officer Immune System Therapeutics

Immune System Therapeutics granted new patent for new method of treating blood cancers

05-Sep-2011 - Immune System Therapeutics Limited (IST) announced it had secured patent protection in Australia for a new method of treating blood cancers that express a target called lambda myeloma antigen (LMA), which was discovered by IST research scientists. This patent is a significant addition to IST’s ...

antibodies Australia blood cancer +1

Immune System Therapeutics completes $2.6 million placement

26-Jul-2011 - Immune System Therapeutics Limited (IST) said it completed a private placement to raise $2 million from new and existing private and institutional investors in Australia. Investors have agreed to purchase 5,200,000 shares in the company at a price of $0.50 cents per share resulting in gross ...

New Australian drug shows positive response in patients with multiple myeloma blood cancer

20-Jun-2011 - Immune System Therapeutics Limited (IST) announced it would double patient recruitment in its Phase II trial for a breakthrough antibody treatment for terminal blood cancer. The trial expansion in Australia follows a positive review of safety and efficacy data by an independent Data Monitoring ...

blood cancer monoclonal antibodies